Egyptian hepatitis b study seeks to uncover drug resistance patterns
NCT ID NCT07274345
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will enroll 2,000 Egyptian patients with chronic hepatitis B to find out how common antiviral drug resistance is and what factors make it more likely. Researchers will look at patients taking common antiviral drugs like tenofovir, entecavir, or lamivudine. The goal is to improve treatment choices and long-term care for hepatitis B patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors choose better antiviral treatments for chronic hepatitis B patients in Egypt, reducing the chance of drug resistance.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly improve patient health. The findings may not apply to other populations or regions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B - ANTIVIRAL DRUG RESISTANCE - HEPATITIS B VIRUS (HBV) INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.